This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Enceladus Pharmaceuticals BV
Drug Names(s): GLPG0303, liposomal prednisolone, long-circulating liposomal prednisolone
Description: Nanocort is composed of prednisolone, a widely used corticosteroid, enclosed in a small lipid vesicle (liposome). The liposomes accumulate at sites of inflammation allowing the delivery of high concentrations of corticosteroid to the sites of action, thereby reducing possible toxicities associated with free glucocorticoids.
Deal Structure: Nanocort was originally developed by Enceladus.
In April 2008, Galapagos in-licensed Nanocort from Enceladus. Under the terms of the agreement, Galapagos will pay Enceladus an upfront fee and run the clinical development of Nanocort. Enceladus will receive a minority share of future revenues received by Galapagos from the commercialization of Nanocort.
In April 2011, Galapagos stated that Nanocort no longer fits in Galapagos' strategy and that the Company sent a termination of collaboration agreement notice to Enceladus.
Pink Sheet Weekly Trademark Review Oct. 21, 2014
Additional information available to subscribers only: